Cardiff Oncology and Pfizer assess onvansertib in metastatic colorectal cancer trial
The ongoing trial of onvansertib in combination with standard therapies for metastatic colorectal cancer could significantly impact treatment options for patients with specific mutations. Success in this trial may enhance Cardiff Oncology's portfolio and strengthen its collaboration with Pfizer, positioning them competitively in the oncology market.
Phase III
metastatic colorectal cancer
Status
Active
Sponsor
Pfizer
Signal Score
8.4
Signal assessment
Signal strength
high
Confidence level
high
Strategic implication
The ongoing trial of onvansertib in combination with standard therapies for metastatic colorectal cancer could significantly impact treatment options for patients with specific mutations. Success in this trial may enhance Cardiff Oncology's portfolio and strengthen its collaboration with Pfizer, positioning them competitively in the oncology market.
Why it matters
The ongoing trial of onvansertib in combination with standard therapies for metastatic colorectal cancer could significantly impact treatment options for patients with specific mutations. Success in this trial may enhance Cardiff Oncology's portfolio and strengthen its collaboration with Pfizer, positioning them competitively in the oncology market.
What changed
Trial Update
Analysis
A clinical trial is underway to evaluate onvansertib combined with standard therapies for first-line treatment of KRAS/NRAS-mutated metastatic colorectal cancer.
The ongoing trial of onvansertib in combination with standard therapies for metastatic colorectal cancer could significantly impact treatment options for patients with specific mutations. Success in this trial may enhance Cardiff Oncology's portfolio and strengthen its collaboration with Pfizer, positioning them competitively in the oncology market.
Monitor trial results for efficacy and safety, particularly the selection of the optimal dosing regimen.
Related companies & assets
Companies
Sources & Humanexa intelligence
Source links
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.